Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Posts 40-percent Gain in Q1 Revenues as Net Loss Declines

NEW YORK, April 27 (GenomeWeb News) - Illumina today reported a 40-percent gain in first-quarter revenues, as total receipts for the quarter ended April 3 climbed to $15.1 million from $10.8 million year over year.

R&D spending increased 13 percent to $5.9 million from $5.2 million in the first quarter of 2004.

Net loss for the quarter fell to $1.2 million, or $.03 per share, from $3.9 million, or $.12 per share, in the first quarter of 2004.

Illumina had cash and cash equivalents of $62.1 million as of April 3.

The San Diego-based company expects second-quarter revenue to range between $15.5 million and $17.5 million, a year-over-year increase of between 35 percent and 52 percent. Illumina also said it expects total revenue for 2005 to range from $75 million to $82 million, a year-over-year increase of between 48 percent and 62 percent.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.